Soiken Holdings Inc. (2385.T)
JPY 122.0
(-1.61%)
JPY 122.0
(-1.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 697.02 Million JPY | -34.72% |
| 2022 | 1.06 Billion JPY | -34.98% |
| 2021 | 1.64 Billion JPY | 79.47% |
| 2020 | 914.99 Million JPY | -43.71% |
| 2019 | 1.62 Billion JPY | 43.81% |
| 2018 | 1.13 Billion JPY | 11.58% |
| 2017 | 1.01 Billion JPY | 14.1% |
| 2016 | 887.84 Million JPY | 42.39% |
| 2015 | 623.54 Million JPY | 136.76% |
| 2014 | 263.36 Million JPY | 7.27% |
| 2013 | 245.53 Million JPY | -2.75% |
| 2012 | 252.47 Million JPY | 11.03% |
| 2011 | 227.39 Million JPY | 15.39% |
| 2010 | 197.06 Million JPY | 15.75% |
| 2009 | 170.25 Million JPY | -43.18% |
| 2008 | 299.66 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 702.43 Million JPY | -22.13% |
| 2023 FY | 697.02 Million JPY | -34.72% |
| 2023 Q3 | 640.52 Million JPY | -8.81% |
| 2023 Q1 | 902.08 Million JPY | -15.52% |
| 2023 Q4 | 697.02 Million JPY | 8.82% |
| 2022 Q1 | 1.15 Billion JPY | -29.52% |
| 2022 FY | 1.06 Billion JPY | -34.98% |
| 2022 Q4 | 1.06 Billion JPY | -27.02% |
| 2022 Q3 | 1.46 Billion JPY | 40.78% |
| 2022 Q2 | 1.03 Billion JPY | -10.2% |
| 2021 Q2 | 1.62 Billion JPY | 39.08% |
| 2021 FY | 1.64 Billion JPY | 79.47% |
| 2021 Q1 | 1.16 Billion JPY | 27.86% |
| 2021 Q4 | 1.64 Billion JPY | 19.13% |
| 2021 Q3 | 1.37 Billion JPY | -15.28% |
| 2020 Q2 | 1.18 Billion JPY | -11.08% |
| 2020 Q3 | 1.07 Billion JPY | -9.82% |
| 2020 FY | 914.99 Million JPY | -43.71% |
| 2020 Q1 | 1.33 Billion JPY | -17.76% |
| 2020 Q4 | 914.99 Million JPY | -14.65% |
| 2019 Q4 | 1.62 Billion JPY | 19.26% |
| 2019 FY | 1.62 Billion JPY | 43.81% |
| 2019 Q1 | 1.23 Billion JPY | 9.69% |
| 2019 Q2 | 1.28 Billion JPY | 3.49% |
| 2019 Q3 | 1.36 Billion JPY | 6.23% |
| 2018 FY | 1.13 Billion JPY | 11.58% |
| 2018 Q2 | 1.11 Billion JPY | -14.23% |
| 2018 Q1 | 1.29 Billion JPY | 28.1% |
| 2018 Q4 | 1.13 Billion JPY | 14.88% |
| 2018 Q3 | 984 Million JPY | -11.6% |
| 2017 FY | 1.01 Billion JPY | 14.1% |
| 2017 Q4 | 1.01 Billion JPY | 31.77% |
| 2017 Q3 | 768.79 Million JPY | 2.94% |
| 2017 Q2 | 746.86 Million JPY | -16.42% |
| 2017 Q1 | 893.55 Million JPY | 0.64% |
| 2016 Q3 | 560.72 Million JPY | -12.21% |
| 2016 FY | 887.84 Million JPY | 42.39% |
| 2016 Q1 | 575.01 Million JPY | -7.78% |
| 2016 Q2 | 638.69 Million JPY | 11.07% |
| 2016 Q4 | 887.84 Million JPY | 58.34% |
| 2015 FY | 623.54 Million JPY | 136.76% |
| 2015 Q4 | 623.54 Million JPY | 55.06% |
| 2015 Q3 | 402.14 Million JPY | 14.6% |
| 2015 Q2 | 350.92 Million JPY | 32.91% |
| 2015 Q1 | 264.02 Million JPY | 0.25% |
| 2014 FY | 263.36 Million JPY | 7.27% |
| 2014 Q3 | 258.98 Million JPY | 7.2% |
| 2014 Q4 | 263.36 Million JPY | 1.69% |
| 2014 Q2 | 241.59 Million JPY | -16.68% |
| 2014 Q1 | 289.96 Million JPY | 18.1% |
| 2013 Q1 | 250.8 Million JPY | -0.66% |
| 2013 Q4 | 245.53 Million JPY | 20.07% |
| 2013 Q3 | 204.48 Million JPY | 15.13% |
| 2013 Q2 | 177.61 Million JPY | -29.18% |
| 2013 FY | 245.53 Million JPY | -2.75% |
| 2012 Q1 | 207.37 Million JPY | -8.8% |
| 2012 Q3 | 199.43 Million JPY | -3.49% |
| 2012 Q4 | 252.47 Million JPY | 26.6% |
| 2012 Q2 | 206.64 Million JPY | -0.35% |
| 2012 FY | 252.47 Million JPY | 11.03% |
| 2011 FY | 227.39 Million JPY | 15.39% |
| 2011 Q2 | 169.16 Million JPY | 1.27% |
| 2011 Q1 | 167.04 Million JPY | -15.24% |
| 2011 Q3 | 167.28 Million JPY | -1.11% |
| 2011 Q4 | 227.39 Million JPY | 35.94% |
| 2010 Q3 | 222.27 Million JPY | 86.68% |
| 2010 FY | 197.06 Million JPY | 15.75% |
| 2010 Q2 | 119.06 Million JPY | -30.45% |
| 2010 Q4 | 197.06 Million JPY | -11.34% |
| 2010 Q1 | 171.18 Million JPY | 0.55% |
| 2009 Q2 | 216.37 Million JPY | 5.79% |
| 2009 Q4 | 170.25 Million JPY | -8.8% |
| 2009 Q3 | 186.67 Million JPY | -13.73% |
| 2009 Q1 | 204.52 Million JPY | -31.75% |
| 2009 FY | 170.25 Million JPY | -43.18% |
| 2008 Q2 | 345.74 Million JPY | 0.0% |
| 2008 FY | 299.66 Million JPY | 0.0% |
| 2008 Q4 | 299.66 Million JPY | -21.19% |
| 2008 Q3 | 380.23 Million JPY | 9.98% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 78.533% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -999.215% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.354% |
| Linical Co., Ltd. | 10.3 Billion JPY | 93.236% |
| Trans Genic Inc. | 3.81 Billion JPY | 81.718% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -18.099% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 76.925% |
| AnGes, Inc. | 2.78 Billion JPY | 75.011% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -35.711% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.229% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -97.305% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 57.753% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -47.563% |
| CanBas Co., Ltd. | 91.98 Million JPY | -657.733% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 36.264% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 13.93% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -17.397% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 83.615% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.606% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -23.04% |
| Ribomic Inc. | 155.8 Million JPY | -347.357% |
| SanBio Company Limited | 2.25 Billion JPY | 69.088% |
| Healios K.K. | 11.28 Billion JPY | 93.824% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -177.401% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -88.895% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -188.626% |
| StemRIM | 187 Million JPY | -272.74% |
| CellSource Co., Ltd. | 677.73 Million JPY | -2.845% |
| FunPep Company Limited | 189.32 Million JPY | -268.164% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -16.763% |
| Stella Pharma Corporation | 1.44 Billion JPY | 51.717% |
| TMS Co., Ltd. | 97.68 Million JPY | -613.512% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -661.824% |
| Cuorips Inc. | 200.96 Million JPY | -246.845% |
| K Pharma,Inc. | 209.13 Million JPY | -233.29% |
| Takara Bio Inc. | 11.42 Billion JPY | 93.896% |
| ReproCELL Incorporated | 741.03 Million JPY | 5.939% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 24.048% |
| StemCell Institute Inc. | 3.85 Billion JPY | 81.898% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 23.272% |
| CellSeed Inc. | 301.04 Million JPY | -131.533% |